Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | XIAP | P98170 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | CASR | P41180 | 2/20 | 0.49 |
| ▸ | KIF11 | P52732 | 3/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.47 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1339972 | 1.00 | ALPI (0.52) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL9404761 | 0.83 | GRIK1 (0.46) | KIF11SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27734502 | 0.83 | KIF11 (0.49) | CASRKIF11MAPT | |
| SCHEMBL27734503 | 0.83 | KIF11 (0.49) | CASRKIF11MAPT | |
| SCHEMBL5406733 | 0.82 | MAPT (0.51) | LTA4HKIF11MAPT | |
| SCHEMBL5406742 | 0.82 | MAPT (0.51) | LTA4HKIF11MAPT | |
| SCHEMBL15547748 | 0.81 | SLC1A3 (0.56) | KIF11SLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL29462213 | 0.81 | SLC1A3 (0.56) | KIF11SLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL20704782 | 0.81 | SLC1A3 (0.56) | KIF11SLC1A3SLC1A2SLC1A1MAPT | |
| SCHEMBL29480617 | 0.81 | SLC1A3 (0.56) | KIF11SLC1A3SLC1A2SLC1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1261601-B1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | claimed |
| EP-1194425-B1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | claimed |
| EP-1531819-A1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-25 | — | — | EP | claimed |
| CN-1172929-C | substituted indoles | ���ĵ�˹ҩ��¹�����˾ | 2004-10-27 | — | — | CN | claimed |
| CN-1168727-C | Substituted benzimidazole | ���ĵ�˹ҩ��¹�����˾ | 2004-09-29 | — | — | CN | claimed |
| US-20040116494-A1 | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | US | claimed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | claimed |
| US-6358978-B1 | FOR THERAPY AND PROPHYLAXIS OF RHEUMATOID ARTHRITIS (IN THE CASE OF INFLAMMATION), OSTEOARTHRITIS, ASTHMA, CARDIAC INFARCT, ALZHEIMER'S DISEASE, OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-19 | — | — | US | claimed |
| EP-2104497-B1 | SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | SANOFI SA (FR) | 2015-02-25 | — | — | EP | disclosed |
| US-8809358-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-8389764-B2 | Urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2104497-A2 | UREA AND SULFAMIDE DERIVATIVES AS TAFIA INHIBITORS | Sanofi-Aventis (FR) | 2009-09-30 | — | — | EP | disclosed |
| EP-1261601-B1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-29 | — | — | EP | disclosed |
| CN-1379772-A | Substituted indoles for modulating NF kappa B activity | AVENTIS PHARMA GMBH (DE) | 2002-11-13 | — | — | CN | disclosed |
| CN-1356995-A | Substituted benzimidazole | AVENTIS PHARMA GMBH (DE) | 2002-07-03 | — | — | CN | disclosed |
| EP-1194425-A1 | SUBSTITUTED BENZIMIDAZOLE | Aventis Pharma Deutschland GmbH (DE) | 2002-04-10 | — | — | EP | disclosed |
| US-6358978-B1 | FOR THERAPY AND PROPHYLAXIS OF RHEUMATOID ARTHRITIS (IN THE CASE OF INFLAMMATION), OSTEOARTHRITIS, ASTHMA, CARDIAC INFARCT, ALZHEIMER'S DISEASE, OR ATHEROSCLEROSIS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-03-19 | — | — | US | disclosed |
| WO-2001030774-A1 | SUBSTITUTED INDOLES FOR MODULATING NFKB ACTIVITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-05-03 | — | — | WO | disclosed |
| WO-2001000610-A1 | SUBSTITUTED BENZIMIDAZOLE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035930-A1 | UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINE1 | ALPI 1385/4885PKM 2526/4885PTGS1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.